Sugi Predict

Sugi Predict / Compounds / SCHEMBL12640087

SCHEMBL12640087

SCHEMBL12640087

O=C(O)c1cc2c(o1)C(=O)c1ccccc1C2=O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 5/20 0.75
▸ ALDH1A1 P00352 3/20 0.75
▸ TTR P02766 5/20 0.49
▸ L3MBTL1 Q9Y468 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ MAPT P10636 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ APAF1 O14727 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ CSNK2A2 P19784 1/20 0.45
▸ PTGS1 P23219 1/20 0.45
▸ CSNK2B P67870 1/20 0.45
▸ CSNK2A1 P68400 1/20 0.45
▸ CSNK2A3 Q8NEV1 1/20 0.45
▸ PTPRC P08575 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ CDC25B P30305 1/20 0.43
▸ BCL2 P10415 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Napabucasin SCHEMBL29349770 0.86 STAT3 (1.00) STAT3ALDH1A1TTRL3MBTL1KMT2A
Napabucasin SCHEMBL1883845 0.86 STAT3 (1.00) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL6001021 0.85 ALDH1A1 (0.69) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL12640086 0.84 STAT3 (0.73) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL18691843 0.84 STAT3 (0.73) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL18691829 0.82 STAT3 (0.65) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL38650880 0.81 STAT3 (0.69) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL12494612 0.81 STAT3 (0.73) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL18730820 0.81 STAT3 (0.69) STAT3ALDH1A1TTRL3MBTL1KMT2A
SCHEMBL16917433 0.79 STAT3 (0.76) STAT3ALDH1A1L3MBTL1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116283935-B Nabuxine-melatonin hybrid and preparation method and application thereof 新乡医学院 2024-11-29 — — CN claimed
EP-4678638-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2026-01-14 — — EP disclosed
CN-116283935-B Nabuxine-melatonin hybrid and preparation method and application thereof 新乡医学院 2024-11-29 — — CN disclosed
EP-4446324-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) 2024-10-16 — — EP disclosed
WO-2024188209-A1 NEW E3 UBIQUITIN LIGASE LIGAND, PROTEIN DEGRADATION AGENT AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-09-19 — — WO disclosed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 — — WO disclosed
WO-2023104155-A1 LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF 标新生物医药科技(上海)有限公司 2023-06-15 — — WO disclosed
CN-109988157-B Novel small molecular compound, preparation method and application in preparation of drug-resistant mycobacterium tuberculosis and other mycobacteria drugs 四川大学 2022-12-27 — — CN disclosed
US-11267797-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2022-03-08 — — US disclosed
US-11267797-B2 Anticancer agent KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2022-03-08 — — US disclosed
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed
US-20170121299-A1 NOVEL ANTICANCER AGENT KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2017-05-04 — — US disclosed
EP-3153508-A1 NOVEL ANTICANCER AGENT Kyoto Pharmaceutical Industries, Ltd. (JP) 2017-04-12 — — EP disclosed
EP-3058941-A1 NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS Boston Biomedical, Inc. (US) 2016-08-24 — — EP disclosed
EP-2194987-B1 NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS BOSTON BIOMEDICAL INC (US) 2016-05-18 — — EP disclosed
US-8877803-B2 Stat3 pathway inhibitors and cancer stem cell inhibitors BOSTON BIOMEDICAL, INC. (US) 2014-11-04 — — US disclosed
US-8877803-B2 Stat3 pathway inhibitors and cancer stem cell inhibitors BOSTON BIOMEDICAL, INC. (US) 2014-11-04 — — US disclosed
US-20110112180-A1 NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS BOSTON BIOMEDICAL, INC. (US) 2011-05-12 — — US disclosed
US-20110112180-A1 NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS BOSTON BIOMEDICAL, INC. (US) 2011-05-12 — — US disclosed
WO-2009036059-A2 NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS BOSTON BIOMEDICAL, INC. (US) 2009-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170121299-A1 NOVEL ANTICANCER AGENT NTPCR, TP53, NME1 STAT3 1231/4885ALDH1A1 187/4885TTR 4750/4885
US-20110112180-A1 NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS STAT3, STAT1, STAT5B STAT3 1/4885ALDH1A1 630/4885TTR 4745/4885
US-11267797-B2 Anticancer agent TP53, NTPCR, NQO1 STAT3 1303/4885ALDH1A1 160/4885TTR 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.